BIIB|Biogen Inc|Preço:193.450|Var. %:2.07

Mais detalhes de Biogen Inc Empresa

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Informações de Biogen Inc



Código da empresaBIIB

Nome da EmpresaBiogen Inc

Data de listagemSep 17, 1991

CEOViehbacher (Christopher A)

Número de funcionários7605

Tipo de títulosOrdinary Share

Fim do ano fiscalSep 17

Endereço225 Binney Street

CidadeCAMBRIDGE

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02142

Telefone17814642000

Sitehttps://www.biogen.com/

Código da empresaBIIB

Data de listagemSep 17, 1991

CEOViehbacher (Christopher A)

Executivos da empresa Biogen Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

Mr. Jesus B. Mantas

Independent Director

8.42K

+28.15%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

8.04K

+12.73%

Dr. Adam James Keeney, Ph.D.

Executive Vice President, Head of Corporate Development

5.88K

+59.46%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+43.29%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

61.89K

+8.95%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+10.82%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

22.10K

+20.79%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

19.61K

+27.48%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

16.08K

+30.17%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+19.19%

Detalhamento da receita

Moeda: USDAtualizado em: seg, 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

Outro

3.25B

32.82%

Por RegiãoUSD

Nome

Receita

Proporção

United States

3.73B

37.67%

Rest of world

3.57B

36.11%

United states-Revenues from anti-CD20 therapeutic

1.86B

18.81%

Rest of World-Other revenues

732.90M

7.41%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Spinal Muscular Atrophy-SPINRAZA

2.15B

21.78%

MS product revenues-TYSABRI

1.67B

16.84%

MS product revenues-Fumarate

1.43B

14.42%

MS product revenues-Interferon

945.60M

9.56%

Biosimilar product revenues-BENEPALI

453.20M

4.58%

Outro

3.25B

32.82%

Distribuição de ações

Atualizado em: há 15 horas

Investidores

Tipos de investidores

Investidores

Proporção

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

Outro

67.39%

Investidores

Proporção

PRIMECAP Management Company

10.00%

Vanguard Capital Management, LLC

6.46%

BlackRock Institutional Trust Company, N.A.

5.91%

Fidelity Management & Research Company LLC

5.40%

State Street Investment Management (US)

4.85%

Outro

67.39%

Tipos de investidores

Investidores

Proporção

Investment Advisor

66.96%

Investment Advisor/Hedge Fund

25.97%

Hedge Fund

6.52%

Pension Fund

3.17%

Research Firm

2.81%

Sovereign Wealth Fund

1.84%

Bank and Trust

1.76%

Individual Investor

0.20%

Family Office

0.16%

Participação acionária institucional



Atualizado em: qui, 9 de abr

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2026Q1

2085

144.76M

98.05%

-3.98M

2025Q4

1994

139.65M

97.81%

+140.37K

2025Q3

2054

139.52M

98.56%

+3.73M

2025Q2

2076

135.78M

99.30%

-133.40K

2025Q1

2125

136.05M

101.20%

-12.08M

2024Q4

2114

138.28M

98.83%

+2.02M

2024Q3

2089

135.94M

98.13%

+100.43K

2024Q2

2100

135.44M

97.85%

-355.51K

2024Q1

2106

135.99M

97.60%

-5.88M

2023Q4

2136

135.17M

94.89%

+4.09M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

PRIMECAP Management Company

14.76M

10.06%

-196.70K

-1.32%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

8.73M

5.95%

+513.30K

+6.25%

Dec 31, 2025

Fidelity Management & Research Company LLC

7.97M

5.43%

+6.90M

+642.96%

Dec 31, 2025

State Street Investment Management (US)

7.16M

4.88%

-160.73K

-2.20%

Dec 31, 2025

Geode Capital Management, L.L.C.

4.20M

2.86%

+130.62K

+3.21%

Dec 31, 2025

Wellington Management Company, LLP

3.55M

2.42%

-695.24K

-16.37%

Dec 31, 2025

Point72 Asset Management, L.P.

2.81M

1.92%

-1.06M

-27.36%

Dec 31, 2025

Norges Bank Investment Management (NBIM)

2.64M

1.8%

+374.66K

+16.55%

Dec 31, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 6 de dez

Nome

Proporção

Invesco Biotechnology & Genome ETF

5.49%

First Trust NASDAQ Pharmaceuticals ETF

4.45%

iShares Neuroscience and Healthcare ETF

4.25%

First Trust NYSE Arca Biotechnology Index Fund

3.53%

VanEck Biotech ETF

3.46%

Invesco Pharmaceuticals ETF

3.01%

iShares Health Innovation Active ETF

2.81%

First Trust Health Care Alphadex Fund

2.4%

ProShares Ultra Nasdaq Biotechnology

2.22%

Alger Russell Innovation ETF

2.21%

Ver Mais

Invesco Biotechnology & Genome ETF

Proporção5.49%

First Trust NASDAQ Pharmaceuticals ETF

Proporção4.45%

iShares Neuroscience and Healthcare ETF

Proporção4.25%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.53%

VanEck Biotech ETF

Proporção3.46%

Invesco Pharmaceuticals ETF

Proporção3.01%

iShares Health Innovation Active ETF

Proporção2.81%

First Trust Health Care Alphadex Fund

Proporção2.4%

ProShares Ultra Nasdaq Biotechnology

Proporção2.22%

Alger Russell Innovation ETF

Proporção2.21%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados